Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Pharmacoeconomic review report. Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDR Recommendation - Pharmacoeconomic Report. 2014 Authors' conclusions The manufacturer's base result suggests that UA is cost-effective compared with LA in that it is both more effective and less costly. The CDR review identified certain weaknesses with assumptions made, and revised values for certain parameters were adopted in reanalysis. However, analysis reached the same conclusion as the manufacturer's submission in that UA was dominant over LA. Indexing Status Subject indexing assigned by CRD MeSH Humans; Leiomyoma; Norpregnadienes Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32014000846 Date abstract record published 17/07/2014 |